Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.14 USD | +2.09% | +4.51% | -12.61% |
Apr. 18 | NeoGenomics, Inc. Announces Senior Leadership Promotions | CI |
Apr. 18 | NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 3.19 times its current sales, is high.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.61% | 1.81B | C- | ||
-17.89% | 8.25B | B+ | ||
+39.20% | 3.57B | C+ | ||
-39.11% | 2.46B | B- | ||
-8.06% | 2.46B | - | ||
-7.35% | 2.38B | B- | ||
-19.01% | 1.55B | A- | ||
-40.66% | 1.21B | C+ | ||
+7.56% | 1.11B | B+ | ||
-15.34% | 1.03B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEO Stock
- Ratings NeoGenomics, Inc.